top of page
reunión de negocios

About us

Lifesome therapeutics is a start-up based in Madrid, dedicated to manufacturing and supplying the next generation of therapeutic drug delivery systems and cutting edge formulas for diagnostics. Connect with the future of personalized medicine!

Innovative technology ready to deliver new therapy solutions

Current Research areas

The science of Lifesome Therapeutics: The background of Ohmline

for cancer treatment

Among dozens of compounds targeting membrane proteins involved in cancer, Ohmline by Lifesome Therapeutics is the only one bearing unique features both as therapeutic agent and nanocarrier, elucidating the potential synergistic effect of this exclusive lipid compound.

as antimicrobial agent

Antibiotic resistance is a main concern among nowadays letal diseases. Lifesome nanotehcnology with intrinsic antimicrobial activity can be used to repurpose antibiotics, tackle antibiotic resistance and improve their therapeutic activity.

Lifesome in numbers




Scientific papers



Meet the team

Advisory Board

Prof. Thierry Lecomte, MD., PhD.

Oncology Expert

Expert in Hepatogastroenterology and Digestive Oncology


Julio Martin, PhD.

Life Science Expert

Life Science and Pharma R&D expert

Prof. Paul-Alain Jaffres, PhD.

Organic Chemistry, Health and Materials Expert

Lipid chemistry, gene delivery and hybrid materials expertise

  • LinkedIn
  • LinkedIn

Key references

1. Coune A., Sculier J.P., Hildebrand J., Frühling J., Strijkmans P., Brassine C., Ghanem G., Ruysschaert J.-M. and Atassi G.(1983)."Iv administration of a water-insoluble antimitotic compound entrapped in liposomes.Preliminary report on infusion of large volumes of liposomes to man. Cancer Treat. Rep., 67(11): 1031-1033. 2. Bery, F., Cancel, M., Guéguinou, M., Potier-Cartereau, M., Vandier, C., Chantôme, A., Guibon, R., Bruyère, F., Fromont, G., Mahéo, K. (2021). Zeb1 and SK3 Channel Are Up-Regulated in Castration-Resistant Prostate Cancer and Promote Neuroendocrine Differentiation. Cancers, 13, 2947. 3. Bauduin, A., Papin, M., Chantôme, A., Couthon, H., Deschamps, L., Requejo-Isidro, J., ... Vandier, C. & Jaffres, P. A. (2021). Development of pyrene-based fluorescent ether lipid as inhibitor of SK3 ion channels. European Journal of Medicinal Chemistry, 209, 112894. 4. Figiel, S., Bery, F., Chantôme, A., Fontaine, D., Pasqualin, C., Maupoil, V., Vandier, C.... & Mahéo, K. (2019). A novel calcium-mediated EMT pathway controlled by lipids: An opportunity for prostate cancer adjuvant therapy. Cancers, 11(11), 1814. 5. Sevrain, C. M., Fontaine, D., Bauduin, A., Guéguinou, M., Zhang, B. L., Chantôme, A.,...Vandier, C. & Jaffres, P. A. (2021). Thio-ether functionalized glycolipid amphiphilic compounds reveal a potent activator of SK3 channel with vasorelaxation effect. Organic & Biomolecular Chemistry, 19(12), 2753-2766. 6. Rua, C., Guéguinou, M., Soubai, I., Viel, E., Potier-Cartereau, M., Chantome, A., ... & Vandier, C. (2018). SK3 gene polymorphism is associated with taxane neurotoxicity and cell calcium homeostasis. Clinical Cancer Research, 24(21), 5313-5320. 7. Herrera, F. E., Sevrain, C. M., Jaffrès, P. A., Couthon, H., Grélard, A., Dufourc, E. J.,Vandier, C. ... & Bouchet, A. M. (2017). Singular interaction between an antimetastatic agent and the lipid bilayer: The Ohmline case. ACS omega, 2(10), 6361-6370. 8. Guéguinou, M., Felix, R., Marionneau-Lambot, S., Oullier, T., Penna, A., Kouba, S., Bouchet, A. M., Vandier, C.... & Potier-Cartereau, M. (2021). Synthetic alkyl-ether-lipid promotes TRPV2 channel trafficking trough PI3K/Akt-girdin axis in cancer cells and increases mammary tumour volume. Cell Calcium, 97, 102435. 9. Berthe, W., Sevrain, C. M., Chantôme, A., Bouchet, A. M., Gueguinou, M., Fourbon, Y.,Vandier, C. ... & Jaffrès, P. A. (2016). New disaccharide‐based ether lipids as SK3 ion channel inhibitors. ChemMedChem, 11(14), 1531-1539. 10. Papin, M., Bouchet, A. M., Chantôme, A., & Vandier, C. (2023). Ether-lipids and cellular signaling: A differential role of alkyl-and alkenyl-ether-lipids. Biochimie. 11. Lonez, C., Vandenbranden, M., & Ruysschaert, J.-M. (2008). Cationic liposomal lipids: from gene carriers to cell signaling. Progress in lipid research, 47(5), 340-347. 12. Sevrain, C. M., Haelters, J. P., Chantôme, A., Couthon-Gourvès, H., Gueguinou, M., Potier-Cartereau, M., ... Vandier, C.& Jaffrès, P. A. (2013). DiGalactosyl-Glycero-Ether Lipid: Synthetic approaches and evaluation as SK3 channel inhibitor. Organic & Biomolecular Chemistry, 11(27), 4479-4487. 13. Chantôme, A., Potier-Cartereau, M., Clarysse, L., Fromont, G., Marionneau-Lambot, S., Guéguinou, M., ... & Vandier, C. (2013). Pivotal role of the lipid Raft SK3–Orai1 complex in human cancer cell migration and bone metastases. Cancer research, 73(15), 4852-4861. 14. Gueguinou, M., Crottès, D., Chantôme, A., Rapetti-Mauss, R., Potier-Cartereau, M., Clarysse, L., ... Vandier, C. & Soriani, O. (2017). The SigmaR1 chaperone drives breast and colorectal cancer cell migration by tuning SK3-dependent Ca2+ homeostasis. Oncogene, 36(25), 3640-3647. 15. Potier, M., Joulin, V., Roger, S., Besson, P., Jourdan, M. L., LeGuennec, J. Y., ... & Vandier, C. (2006). Identification of SK3 channel as a new mediator of breast cancer cell migration. Molecular cancer therapeutics, 5(11), 2946-2953. 16. Guéguinou, M., Harnois, T., Crottes, D., Uguen, A., Deliot, N., Gambade, A.,Vandier, C. ... & Potier-Cartereau, M. (2016). SK3/TRPC1/Orai1 complex regulates SOCE-dependent colon cancer cell migration: A novel opportunity to modulate anti-EGFR mAb action by the alkyl-lipid Ohmline. Oncotarget, 7(24), 36168. 17. Jaffres, P. A., Gajate, C., Bouchet, A. M., Couthon-Gourves, H., Chantôme, A., Potier-Cartereau, M., ... & Vandier, C. (2016). Alkyl ether lipids, ion channels and lipid raft reorganization in cancer therapy. Pharmacology & Therapeutics, 165, 114-131. 18. Gueguinou, M., Gambade, A., Félix, R., Chantôme, A., Fourbon, Y., Bougnoux, P., ... & Vandier, C. (2015). Lipid rafts, KCa/ClCa/Ca2+ channel complexes and EGFR signaling: Novel targets to reduce tumor development by lipids. Biochimica et Biophysica Acta (BBA)-Biomembranes, 1848(10), 2603-2620. 19. Girault, A., Haelters, J. P., Potier-Cartereau, M., Chantôme, A., Pinault, M., Marionneau-Lambot, S., ... & Vandier, C. (2011). New alkyl-lipid blockers of SK3 channels reduce cancer cell migration and occurrence of metastasis. Current cancer drug targets, 11(9), 1111-1125. 20. Lonez C, Vandenbranden M, Ruysschaert J.-M.. (2012) Cationic lipids activate intracellular signaling pathways. Adv Drug Deliv Rev. 64(15):1749-58.


bottom of page